LTD4 induces HB-EGF-dependent CXCL8 release through EGFR activation in human bronchial epithelial cells

Toby McGovern, Paul-André Risse, Kimitake Tsuchiya, Muhannad Hassan, Gerard Frigola, James G. Martin
2010 American Journal of Physiology - Lung cellular and Molecular Physiology  
Airway epithelial cells release proinflammatory mediators that may contribute to airway remodeling and leukocyte recruitment. We explored the hypothesis that leukotriene D 4 (LTD4) may trigger the release of proremodeling factors through activation of the EGF receptor (EGFR). We particularly focused on the effects of LTD 4 on release of heparin-binding EGF-like factor (HB-EGF) and IL-8 (CXCL8), a potent neutrophil chemoattractant that may be released downstream of EGFR activation. To address
more » ... s hypothesis, both primary (NHBE) and transformed bronchial human epithelial cells (BEAS-2B) were grown on an air-liquid interface and stimulated with LTD 4. HB-EGF and CXCL8 were evaluated by ELISA in cell culture supernatants. To explore the EGFR signaling pathway, we used a broad-spectrum matrix metalloproteinase (MMP) inhibitor, GM-6001, two selective EGFR tyrosine kinase inhibitors, AG-1478 and PD-153035, an HB-EGF neutralizing antibody, and a specific small interfering RNA (siRNA) against the EGFR. Expression of the CysLT 1 cysteinyl leukotriene receptor was demonstrated by RT-PCR and immunocytochemistry in both BEAS-2B and NHBE cells. Four hours after stimulation with LTD 4, HB-EGF and CXCL8 were significantly increased in cell culture supernatant. GM-6001 and montelukast, a specific CysLT1 receptor antagonist, blocked the LTD4-induced increase in HB-EGF. All inhibitors/antagonists decreased LTD4-induced CXCL8 release. siRNA against EGFR abrogated CXCL8 release following stimulation with LTD4 and exogenous HB-EGF. These findings suggest LTD4 induced EGFR transactivation through the release of HB-EGF in human bronchial epithelial cells with downstream release of CXCL8. These effects may contribute to epithelial-mediated airway remodeling in asthma and other conditions associated with cysteinyl leukotriene release. cysteinyl leukotrienes; heparin-binding-epidermal growth factor-like factor; interleukin-8; leukotriene D4 CYSTEINYL LEUKOTRIENES (CysLTs) are potent lipid mediators derived from the arachidonic acid pathway that comprise leukotriene (LT) C 4 , LTD 4 , and LTE 4 (3) . In the lung, CysLTs are mainly synthesized by mast cells, basophils, eosinophils, macrophages, neutrophils, and epithelial cells in response to a variety of stimuli (3). CysLTs are involved in the pathophysiology of asthma and contribute by causing bronchoconstriction, edema, mucus secretion, and increased inflammatory cell recruitment to the airways (14). High concentrations of CysLTs are present in the sputum of patients that have moderate to severe asthma in the course of acute exacerbations (1). CysLTs are also elevated in the sputum of patients with cystic Address for reprint requests and other correspondence: J. G.
doi:10.1152/ajplung.00438.2009 pmid:20889674 fatcat:6sw2dp4ebrcvlkkpdznf7mhbjq